Abstract
Original language | English |
---|---|
Article number | 54 |
Journal | Annals of clinical microbiology and antimicrobials |
Volume | 21 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Dec 2022 |
Keywords
- Antimicrobial resistance
- Colonization
- Empirical antibiotic therapy
- Febrile neutropenia
- Resistance surveillance
- Third-generation-cephalosporin resistance
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of clinical microbiology and antimicrobials, Vol. 21, No. 1, 54, 01.12.2022.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Third-generation cephalosporin resistant gram-negative bacteraemia in patients with haematological malignancy; an 11-year multi-centre retrospective study
AU - de la Court, Jara R.
AU - Woudt, Sjoukje H. S.
AU - Schoffelen, Annelot F.
AU - Heijmans, Jarom
AU - de Jonge, Nick A.
AU - van der Bruggen, Tjomme
AU - Bomers, Marije K.
AU - Lambregts, Merel M. C.
AU - Schade, Rogier P.
AU - Sigaloff, Kim C. E.
AU - ISIS-AR study group
AU - Stuart, J. W. T. Cohen
AU - Melles, D. C.
AU - van Dijk, K.
AU - Alzubaidy, A.
AU - Werdmuller, B. F. M.
AU - Blaauw, G. J.
AU - Diederen, B. M. W.
AU - Alblas, H. J.
AU - der Kuil, W. Altorf-van
AU - Bierman, S. M.
AU - de Greeff, S. C.
AU - Groenendijk, S. R.
AU - Hertroys, R.
AU - Kuijper, E. J.
AU - Monen, J. C.
AU - Notermans, D. W.
AU - van den Reek, W. J.
AU - Smilde, A. E.
AU - Wielders, C. C. H.
AU - Zoetigheid, R. E.
AU - van den Bijllaardt, W.
AU - Kraan, E. M.
AU - Mattsson, E. E.
AU - da Silva, J. M.
AU - de Jong, E.
AU - Maraha, B.
AU - van Asselt, G. J.
AU - Demeulemeester, A.
AU - Wintermans, B. B.
AU - van Trijp, M.
AU - Ott, A.
AU - Sinnige, J.
AU - Melles, D. C.
AU - Silvis, W.
AU - Bakker, L. J.
AU - Dorigo-Zetsma, J. W.
AU - Waar, K.
AU - Bernards, A. T.
AU - van Rijn, M.
AU - Overdevest, I. T. M. A.
AU - Hall, M. A. Leversteijn-van
N1 - Funding Information: The Dutch national antimicrobial resistance surveillance system (ISIS-AR) is supported by the Dutch Ministry of Health, Welfare and Sport. This study was conducted as part of the authors’ routine work and the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: Members of the ISIS-AR study group are listed in the acknowledgements section. Members of the ISIS-AR study group: J.W.T. Cohen Stuart, Noordwest Ziekenhuisgroep, Department of Medical Microbiology, Alkmaar; D.C. Melles, Meander Medical Center, Department of Medical Microbiology, Amersfoort; K. van Dijk, Amsterdam UMC, Universiteit van Amsterdam, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam; A. Alzubaidy, Atalmedial, Department of Medical Microbiology, Amsterdam; B.F.M. Werdmuller, Public Health Service, Public Health Laboratory, Amsterdam; G.J. Blaauw, Gelre Hospitals, Department of Medical Microbiology and Infection prevention, Apeldoorn; B.M.W. Diederen, Bravis Hospital, Department of Medical Microbiology, Bergen op Zoom; ISIS-AR project team: H.J. Alblas, W. Altorf-van der Kuil, S.M. Bierman, S.C. de Greeff, S.R. Groenendijk, R. Hertroys, E.J. Kuijper, J.C. Monen, D.W. Notermans, W.J. van den Reek, A.F. Schoffelen, A.E. Smilde, C.C.H. Wielders, S.H.S. Woudt, R.E. Zoetigheid, Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven; W. van den Bijllaardt, Microvida Amphia, Laboratory for Microbiology and Infection Control, Breda; E.M. Kraan, IJsselland hospital, Department of Medical Microbiology, Capelle a/d IJssel; E.E. Mattsson, Reinier de Graaf Groep, Department of Medical Microbiology, Delft; J.M. da Silva, Deventer Hospital, Department of Medical Microbiology, Deventer; E. de Jong, Slingeland Hospital, Department of Medical Microbiology, Doetinchem; B. Maraha, Albert Schweitzer Hospital, Department of Medical Microbiology, Dordrecht; A.J. van Griethuysen, Gelderse Vallei Hospital, Department of Medical Microbiology, Ede; G.J. van Asselt, SHL-Groep, Etten-Leur; A. Demeulemeester, SHL-Groep, Etten-Leur; B.B. Wintermans, Admiraal De Ruyter Hospital, Department of Medical Microbiology, Goes; M. van Trijp, Groene Hart Hospital, Department of Medical Microbiology and Infection Prevention, Gouda; A. Ott, Certe, Department of Medical Microbiology, Groningen; J. Sinnige, Regional Laboratory of Public Health, Haarlem; D.C. Melles, St Jansdal Hospital, Department of Medical Microbiology, Harderwijk; W. Silvis, Laboratory of Medical Microbiology and Public Health, Hengelo; L.J. Bakker, CBSL, Tergooi Hospital, Department of Medical Microbiology, Hilversum; J.W. Dorigo-Zetsma, CBSL, Tergooi Hospital, Department of Medical Microbiology, Hilversum; K. Waar, Izore Centre for Infectious Diseases Friesland, Leeuwarden; A.T. Bernards, Leiden University Medical Center, Department of Medical Microbiology, Leiden; M.A. Leversteijn-van Hall, Alrijne Hospital, Department of Medical Microbiology, Leiden-Leiderdorp; E. Schaftenaar, St Antonius Hospital, Department of Medical Microbiology and Immunology, Nieuwegein; M.H. Nabuurs-Franssen, Canisius Wilhelmina Hospital, Department of Medical Microbiology and Infectious Diseases, Nijmegen; H. Wertheim, Radboud University Medical Center, Department of Medical Microbiology, Nijmegen; B.M.W. Diederen, Bravis Hospital, Department of Medical Microbiology, Roosendaal; L. Bode, Erasmus University Medical Center, Department of Medical Microbiology, Rotterdam; M. van Rijn, Ikazia Hospital, Department of Medical Microbiology, Rotterdam; S. Dinant, Maasstad Hospital, Department of Medical Microbiology, Rotterdam; O. Pontesilli, Maasstad Hospital, Department of Medical Microbiology, Rotterdam; P. de Man, Franciscus Gasthuis and Vlietland, Department of Medical Microbiology and Infection Control, Rotterdam; M. Wong, Haga Hospital, Department of Medical Microbiology, 's-Gravenhage; A.E. Muller, MCH Westeinde Hospital, Department of Medical Microbiology, 's-Gravenhage; N.H. Renders, Jeroen Bosch Hospital, Department of Medical Microbiology and Infection Control, 's-Hertogenbosch; R.G. Bentvelsen, Microvida ZorgSaam, Department of Medical Microbiology, Terneuzen; A.G.M. Buiting, St. Elisabeth Hospital, Department of Medical Microbiology, Tilburg; A.L.M. Vlek, Diakonessenhuis, Department of Medical Microbiology and Immunology, Utrecht; A.J. Stam, Saltro Diagnostic Centre, Department of Medical Microbiology, Utrecht; A. Troelstra, University Medical Center Utrecht, Department of Medical Microbiology, Utrecht; I.T.M.A. Overdevest, PAMM, Department of Medical Microbiology, Veldhoven; M.P.A. van Meer, Rijnstate Hospital, Laboratory for Medical Microbiology and Immunology, Velp; C. Oliveira dos Santos, Isala Hospital, Laboratory of Medical Microbiology and Infectious Diseases, Zwolle; M.J.H.M. Wolfhagen, Isala Hospital, Laboratory of Medical Microbiology and Infectious Diseases, Zwolle Publisher Copyright: © 2022, The Author(s).
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Objectives: Among patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative bacteria (GNB) to third-generation cephalosporins (3GC) is increasing. In order to explore the value of using surveillance cultures to guide empirical treatment e.g. choosing between carbapenem versus ceftazidime- we aimed to assess the distribution of pathogens causing bacteraemia in patients with haematological malignancy, and the proportion of 3GC-resistant GNB (3GC-R GNB) bacteraemia that was preceded by 3GC-R GNB colonization. Methods: Using 11 years of data (2008–2018) from the Dutch national antimicrobial resistance surveillance system, we assessed the prevalence of 3GC-R GNB in episodes of bacteraemia, and the proportion of 3GC-R GNB bacteraemia that was preceded by 3GC-R GNB colonization. Colonization was defined as availability of any GNB surveillance isolate in the year before, independent of the causative micro-organism (time-paired isolates). Results: We included 3887 patients, representing 4142 episodes of bacteraemia. GNB were identified in 715/4142 (17.3%), of which 221 (30.9%) were 3GC-R GNB. In 139 of these 221 patients a time-paired surveillance culture was available. In 76.2% (106/139) of patients these surveillance cultures already showed 3GC-R GNB isolates in the year prior to the culture date of the 3GC-R GNB positive blood isolate. Conclusions: This multi-centre study shows that in patients with haematological malignancy, the majority of 3GC-R GNB bacteraemia is preceded by 3GC-R GNB colonization. Prospective clinical studies are needed to assess the safety and benefits of the use of surveillance-cultures to guide empirical therapy to restrict the empirical use of carbapenems in this population.
AB - Objectives: Among patients with haematological malignancy, bacteraemia is a common complication during chemotherapy-induced neutropenia. Resistance of gram-negative bacteria (GNB) to third-generation cephalosporins (3GC) is increasing. In order to explore the value of using surveillance cultures to guide empirical treatment e.g. choosing between carbapenem versus ceftazidime- we aimed to assess the distribution of pathogens causing bacteraemia in patients with haematological malignancy, and the proportion of 3GC-resistant GNB (3GC-R GNB) bacteraemia that was preceded by 3GC-R GNB colonization. Methods: Using 11 years of data (2008–2018) from the Dutch national antimicrobial resistance surveillance system, we assessed the prevalence of 3GC-R GNB in episodes of bacteraemia, and the proportion of 3GC-R GNB bacteraemia that was preceded by 3GC-R GNB colonization. Colonization was defined as availability of any GNB surveillance isolate in the year before, independent of the causative micro-organism (time-paired isolates). Results: We included 3887 patients, representing 4142 episodes of bacteraemia. GNB were identified in 715/4142 (17.3%), of which 221 (30.9%) were 3GC-R GNB. In 139 of these 221 patients a time-paired surveillance culture was available. In 76.2% (106/139) of patients these surveillance cultures already showed 3GC-R GNB isolates in the year prior to the culture date of the 3GC-R GNB positive blood isolate. Conclusions: This multi-centre study shows that in patients with haematological malignancy, the majority of 3GC-R GNB bacteraemia is preceded by 3GC-R GNB colonization. Prospective clinical studies are needed to assess the safety and benefits of the use of surveillance-cultures to guide empirical therapy to restrict the empirical use of carbapenems in this population.
KW - Antimicrobial resistance
KW - Colonization
KW - Empirical antibiotic therapy
KW - Febrile neutropenia
KW - Resistance surveillance
KW - Third-generation-cephalosporin resistance
UR - http://www.scopus.com/inward/record.url?scp=85142882245&partnerID=8YFLogxK
U2 - https://doi.org/10.1186/s12941-022-00544-0
DO - https://doi.org/10.1186/s12941-022-00544-0
M3 - Article
C2 - 36443758
SN - 1476-0711
VL - 21
JO - Annals of clinical microbiology and antimicrobials
JF - Annals of clinical microbiology and antimicrobials
IS - 1
M1 - 54
ER -